$BFRI
Biofrontera Inc Stock $bfri

$bfri Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224010133 Filed on March 15, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$7.912M	$10.60M	$34.07M
YoY Change	-9.4%	4.46%	18.82%
Cost Of Revenue	$4.116M	$5.368M	$17.44M
YoY Change	-10.48%	2.13%	14.88%
Gross Profit	$3.796M	$5.228M	$16.63M
YoY Change	-8.2%	6.96%	23.26%
Gross Profit Margin	47.98%	49.34%	48.8%
Selling, General & Admin	$9.250M	$9.060M	$37.80M
YoY Change	-5.61%	-11.25%	7.58%
% of Gross Profit	243.68%	173.3%	227.35%
Research & Development	$17.00K		$77.00K
YoY Change
% of Gross Profit	0.45%		0.46%
Depreciation & Amortization	$21.00K	$125.0K	$504.0K
YoY Change	-4.55%	0.0%	404.0%
% of Gross Profit	0.55%	2.39%	3.03%
Operating Expenses	$13.38M	$9.060M	$38.00M
YoY Change	-5.95%	-13.78%	-19.58%
Operating Profit	-$5.467M	-$3.832M	-$21.38M
YoY Change	-0.6%	-31.81%	15.04%
Interest Expense	$1.421M	-$998.0K	-$7.889M
YoY Change	70950.0%	2751.43%	-4145.64%
% of Operating Profit
Other Income/Expense, Net	-$4.969M	$998.0K	$3.064M
YoY Change	150.83%	-65.24%	-82.95%
Pretax Income	-$10.44M	$3.520M	-$20.12M
YoY Change	39.65%	-226.44%	3208.72%
Income Tax	$1.000K	-$6.000K	$14.00K
% Of Pretax Income		-0.17%
Net Earnings	-$10.44M	$3.526M	-$20.13M
YoY Change	39.57%	-226.61%	3045.47%
Net Earnings / Revenue	-131.91%	33.28%	-59.09%
Basic Earnings Per Share	-$2.88		-$13.02
Diluted Earnings Per Share	-$2.88	$2.28	-$13.02
COMMON SHARES
Basic Shares Outstanding	5.089M shares	1.518M shares	1.546M shares
Diluted Shares Outstanding	3.624M shares		1.546M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.840M	$1.421M	$1.421M
YoY Change	-81.8%	-94.9%	-94.9%
Cash & Equivalents	$3.817M	$1.343M	$1.343M
Short-Term Investments	$23.00K	$78.00K	$78.00K
Other Short-Term Assets	$5.719M	$5.584M	$5.584M
YoY Change	260.59%	670.21%	670.21%
Inventory	$6.905M	$10.91M	$10.91M
Prepaid Expenses		$305.0K
Receivables	$3.691M	$5.162M	$5.162M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.16M	$23.08M	$23.08M
YoY Change	-45.85%	-46.51%	-46.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$120.0K	$1.746M	$1.746M
YoY Change	-39.09%	755.88%	10.58%
Goodwill
YoY Change
Intangibles	$2.556M	$2.629M
YoY Change	-12.68%	-13.29%
Long-Term Investments
YoY Change
Other Assets	$328.0K	$482.0K	$482.0K
YoY Change	-14.58%	50.63%	50.63%
Total Long-Term Assets	$4.420M	$4.857M	$4.857M
YoY Change	-6.79%	-37.28%	-37.28%
TOTAL ASSETS
Total Short-Term Assets	$20.16M	$23.08M	$23.08M
Total Long-Term Assets	$4.420M	$4.857M	$4.857M
Total Assets	$24.58M	$27.93M	$27.93M
YoY Change	-41.44%	-45.11%	-45.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.761M	$9.006M	$9.006M
YoY Change	662.23%	604.69%	247.72%
Accrued Expenses	$4.230M	$4.492M	$4.492M
YoY Change	-62.01%	-58.65%	-59.13%
Deferred Revenue
YoY Change
Short-Term Debt	$2.355M	$3.904M	$3.904M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.04M	$18.09M	$18.09M
YoY Change	-31.36%	-13.43%	-13.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$33.00K	$5.051M	$5.051M
YoY Change	37.5%	23952.38%	-17.36%
Total Long-Term Liabilities	$33.00K	$5.051M	$5.051M
YoY Change	37.5%	23952.38%	-17.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.04M	$18.09M	$18.09M
Total Long-Term Liabilities	$33.00K	$5.051M	$5.051M
Total Liabilities	$26.42M	$23.14M	$23.14M
YoY Change	4.79%	-14.32%	-14.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.1M	-$99.70M
YoY Change	26.55%	25.41%
Common Stock	$5.000K	$2.000K
YoY Change	-81.48%	-92.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.416M	$4.793M	$4.793M
YoY Change
Total Liabilities & Shareholders Equity	$24.58M	$27.93M	$27.93M
YoY Change	-41.44%	-45.11%	-45.11%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$10.44M	$3.526M	-$20.13M
YoY Change	39.57%	-226.61%	3045.47%
Depreciation, Depletion And Amortization	$21.00K	$125.0K	$504.0K
YoY Change	-4.55%	0.0%	404.0%
Cash From Operating Activities	-$3.325M	-$8.866M	-$24.90M
YoY Change	-10.14%	7.19%	53.67%
INVESTING ACTIVITIES
Capital Expenditures	$57.00K	-$9.000K	$5.000K
YoY Change	307.14%	-1000.0%	-86.84%
Acquisitions
YoY Change
Other Investing Activities	$57.00K	$64.00K	$624.0K
YoY Change		-103.07%	-112.19%
Cash From Investing Activities		$73.00K	$619.0K
YoY Change		-103.5%	-112.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$4.507M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$5.799M	6.714M	8.411M
YoY Change			-40.01%
NET CHANGE
Cash From Operating Activities	-$3.325M	-8.866M	-24.90M
Cash From Investing Activities		73.00K	619.0K
Cash From Financing Activities	$5.799M	6.714M	8.411M
Net Change In Cash	$2.474M	-2.079M	-15.87M
YoY Change	-166.81%	-79.93%	116.32%
FREE CASH FLOW
Cash From Operating Activities	-$3.325M	-$8.866M	-$24.90M
Capital Expenditures	$57.00K	-$9.000K	$5.000K
Free Cash Flow	-$3.382M	-$8.857M	-$24.90M
YoY Change	-8.94%	7.07%	53.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001858685
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent		usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings		usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2022	BFRI	Excess Of Warrant Fair Value Over Offering Proceeds ExcessOfWarrantFairValueOverOfferingProceeds		usd
CY2022	BFRI	Gain Loss On Legal Settlement GainLossOnLegalSettlement		usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement		usd
CY2022	BFRI	Excess Of Warrant Fair Value Over Offering Proceeds ExcessOfWarrantFairValueOverOfferingProceeds		usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets		usd
CY2023	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi		usd
CY2022	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi		usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2023	BFRI	Proceeds From Exercise Of Warrants ProceedsFromExerciseOfWarrants		usd
CY2022	BFRI	Interest Paid Related Party InterestPaidRelatedParty		usd
CY2022	BFRI	Release Of Startup Cost Financing Obligation As Part Of Legal Settlement ReleaseOfStartupCostFinancingObligationAsPartOfLegalSettlement		usd
CY2022	BFRI	Release Of Contingent Consideration Obligation As Part Of Legal Settlement ReleaseOfContingentConsiderationObligationAsPartOfLegalSettlement		usd
CY2022	BFRI	Transfer Of Investment As Part Of Legal Settlement TransferOfInvestmentAsPartOfLegalSettlement		usd
CY2023	BFRI	Conversion Of Warrant Liability To Equity In Connection With Exercise Of Warrants ConversionOfWarrantLiabilityToEquityInConnectionWithExerciseOfWarrants		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability		usd
CY2023	BFRI	Fair Value Warrant Exercise Of Derivative Liabilities FairValueWarrantExerciseOfDerivativeLiabilities		usd
CY2022	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi		usd
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss		usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets		usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits		pure
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost		usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022	BFRI	Interest Expenses Related Party InterestExpensesRelatedParty		usd
CY2023	us-gaap	Interest Income Operating InterestIncomeOperating		usd
CY2023Q4	BFRI	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40943
CY2023	dei	Entity Registrant Name EntityRegistrantName	BIOFRONTERA INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3765675
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	120 Presidential Way
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 330
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Woburn
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01801
CY2023	dei	City Area Code CityAreaCode	(781)
CY2023	dei	Local Phone Number LocalPhoneNumber	245-1325
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	14200000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5089413	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	East Hanover, New Jersey
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1343000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17208000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	5162000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	3748000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	10908000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	7168000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	425000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	810000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	23075000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	43140000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	134000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	204000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1612000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1375000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2629000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3032000	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	482000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	320000	usd
CY2023Q4	us-gaap	Assets Assets	27932000	usd
CY2022Q4	us-gaap	Assets Assets	50884000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	6942000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	691000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	498000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4487000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10864000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	3904000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18088000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20894000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2400000	usd
CY2023Q4	BFRI	Warrant Liabilities Non Current WarrantLiabilitiesNonCurrent	4210000	usd
CY2022Q4	BFRI	Warrant Liabilities Non Current WarrantLiabilitiesNonCurrent	2843000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	804000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	848000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	23139000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	27006000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	1747000	usd
CY2023	BFRI	Gain Loss On Legal Settlement GainLossOnLegalSettlement	7385000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-468000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-195000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-75000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1517628	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1517628	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1334950	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1334950	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104441000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	103396000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-99650000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79519000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4793000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23878000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27932000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50884000	usd
CY2023	BFRI	Products Revenues Net ProductsRevenuesNet	34005000	usd
CY2022	BFRI	Products Revenues Net ProductsRevenuesNet	28541000	usd
CY2023	BFRI	Revenues Related Party RevenuesRelatedParty	66000	usd
CY2022	BFRI	Revenues Related Party RevenuesRelatedParty	133000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34071000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28674000	usd
CY2023	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	16789000	usd
CY2022	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	14618000	usd
CY2023	BFRI	Cost Of Revenues Other CostOfRevenuesOther	655000	usd
CY2022	BFRI	Cost Of Revenues Other CostOfRevenuesOther	567000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38975000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35137000	usd
CY2023	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	152000	usd
CY2022	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	733000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	100000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3800000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	56748000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	47255000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-22677000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18581000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6456000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19017000	usd
CY2023	BFRI	Warrant Inducement Expense WarrantInducementExpense	1045000	usd
CY2022	BFRI	Warrant Inducement Expense WarrantInducementExpense	2629000	usd
CY2023	BFRI	Excess Of Warrant Fair Value Over Offering Proceeds ExcessOfWarrantFairValueOverOfferingProceeds	-2272000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-7421000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2560000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17973000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20117000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-608000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20131000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-640000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.02
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-13.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1546297	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1546297	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1056988	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1056988	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11338000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3683000	usd
CY2022	BFRI	Stock Issued During Period Value Private Placement Offering StockIssuedDuringPeriodValuePrivatePlacementOffering	117000	usd
CY2022	BFRI	Stock Issued During Period Value Exercise Of Prefunded Warrants StockIssuedDuringPeriodValueExerciseOfPrefundedWarrants	2842000	usd
CY2022	BFRI	Stock Issued During Period Value Exercise Of Pipe Warrants StockIssuedDuringPeriodValueExerciseOfPipeWarrants	4686000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1852000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-640000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23878000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23878000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023	BFRI	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	usd
CY2023	BFRI	Stock Issued During Period Value Issuance Of Common Stock And Warrants Under Registered Public Offering StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsUnderRegisteredPublicOffering	1000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1045000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20131000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4793000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4793000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20131000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-640000	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	7385000	usd
CY2023	us-gaap	Depreciation Depreciation	86000	usd
CY2022	us-gaap	Depreciation Depreciation	101000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	560000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	653000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	418000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	418000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-7421000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1747000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	100000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3800000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6456000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19017000	usd
CY2023	BFRI	Warrant Inducement Expense WarrantInducementExpense	1045000	usd
CY2022	BFRI	Warrant Inducement Expense WarrantInducementExpense	2629000	usd
CY2023	BFRI	Excess Of Warrant Fair Value Over Offering Proceeds ExcessOfWarrantFairValueOverOfferingProceeds	-2272000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1045000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1852000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	100000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	122000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	106000	usd
CY2023	BFRI	Noncash Interest Expense NoncashInterestExpense	402000	usd
CY2022	BFRI	Noncash Interest Expense NoncashInterestExpense	358000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1536000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	70000	usd
CY2023	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	-6470000	usd
CY2022	us-gaap	Increase Decrease In Due From Other Related Parties Current IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent	-4990000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-174000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4154000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	5159000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3750000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2810000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	6415000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	912000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-657000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-781000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6351000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3607000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24895000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16199000	usd
CY2022	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	5118000	usd
CY2023	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	624000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	38000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	619000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5156000	usd
CY2023	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	21448000	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	3800000	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	21344000	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	4507000	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	9391000	usd
CY2022	BFRI	Proceeds From Exercise Of Warrants ProceedsFromExerciseOfWarrants	4630000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8411000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14021000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15865000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7334000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17408000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24742000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1543000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17408000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	125000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1000	usd
CY2023	BFRI	Interest Paid Related Party InterestPaidRelatedParty	22000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	15000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	32000	usd
CY2023	BFRI	Release Of Startup Cost Financing Obligation As Part Of Legal Settlement ReleaseOfStartupCostFinancingObligationAsPartOfLegalSettlement	-7300000	usd
CY2023	BFRI	Release Of Contingent Consideration Obligation As Part Of Legal Settlement ReleaseOfContingentConsiderationObligationAsPartOfLegalSettlement	-2500000	usd
CY2023	BFRI	Transfer Of Investment As Part Of Legal Settlement TransferOfInvestmentAsPartOfLegalSettlement	2415000	usd
CY2023	BFRI	Addition Of Rightofuse Assets In Exchange For Operating Lease Liabilities AdditionOfRightofuseAssetsInExchangeForOperatingLeaseLiabilities	800000	usd
CY2022	BFRI	Addition Of Rightofuse Assets In Exchange For Operating Lease Liabilities AdditionOfRightofuseAssetsInExchangeForOperatingLeaseLiabilities	234000	usd
CY2022	BFRI	Conversion Of Warrant Liability To Equity In Connection With Exercise Of Warrants ConversionOfWarrantLiabilityToEquityInConnectionWithExerciseOfWarrants	6840000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	3683000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24900000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16200000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-99700000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4100000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1300000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17200000	usd
CY2023	BFRI	Discretionary Expenses DiscretionaryExpenses	5500000	usd
CY2023Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-20 reverse stock split
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_z641Dh6YPeGg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Use of Estimates</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The preparation of the consolidated financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions by management that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities, as reported on the balance sheet date, and the reported amounts of revenues and expenses arising during the reporting period. The main areas in which assumptions, estimates and the exercising of judgment are appropriate relate to realization and valuation of receivables and inventory, valuation of contingent consideration and warrant liabilities, impairment assessment of intangibles and other long-lived assets, share-based payments, income taxes including deferred tax assets and liabilities and contingent liability recognition. Estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances. They are continuously reviewed but may vary from the actual values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1000000.0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_z777Um7HIhE1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_860_zMQs2Uw29bKh">Concentration of Credit Risk and Off-Balance Sheet Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, accounts receivable and other receivables, related party. The Company maintains all of its cash and cash equivalents at a single accredited financial institution, in amounts that exceed federally insured limits. The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers using our products. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_906_eus-gaap--ConcentrationRiskLicense_c20230101__20231231_zC9LePu7agfj" title="Concentration risk license, descriptions">The Company has a receivable due from Biofrontera AG for its 50% share of a legal settlement and related costs for which they are jointly and severally liable for the total settlement amount. The Company has a contractual right to repayment of its share of the settlement payment from Biofrontera AG under the Settlement Allocation Agreement entered into on December 9, 2021, which provided that the settlement payments would first be made by the Company and then reimbursed by Biofrontera AG for its share. Although this receivable has credit risk, it is mitigated by the Settlement Allocation Agreement as amended on March 31, 2022, which provides certain remedies to the Company, if Biofrontera AG fails to make timely reimbursements, which the Company may implement in its sole discretion, including the ability to charge interest at a rate of 6.0% per annum for each day that any reimbursement is past due and the ability to offset any overdue reimbursement amounts against payments owed to Biofrontera AG by the Company</span> (including amounts owed under the Company’s license and supply agreement for Ameluz<sup>®</sup>). The Addendum to Amended and Restated License and Supply Agreement, effective December 5, 2023, and as amended on January 29, 2024, allows for the Company to set off the amounts due to Biofrontera AG and Ameluz Licensor, with the amounts due from Biofrontera AG and Ameluz Licensor. As such, in accordance with ASC 210-20-45-1 the other receivables, related party have been offset against accounts payable, related parties for the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We are dependent on two licensors, Biofrontera Pharma and Ferrer, to supply drug products, including all underlying components, for our commercial efforts. These efforts could be adversely affected by a significant interruption in the supply of our finished products. These licensors may have risks associated with limited source suppliers and contract manufacturers. If our licensors fail to maintain relationships with these suppliers and manufacturers or they are unable to produce product, our business could be materially harmed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2023	us-gaap	Concentration Risk License ConcentrationRiskLicense	The Company has a receivable due from Biofrontera AG for its 50% share of a legal settlement and related costs for which they are jointly and severally liable for the total settlement amount. The Company has a contractual right to repayment of its share of the settlement payment from Biofrontera AG under the Settlement Allocation Agreement entered into on December 9, 2021, which provided that the settlement payments would first be made by the Company and then reimbursed by Biofrontera AG for its share. Although this receivable has credit risk, it is mitigated by the Settlement Allocation Agreement as amended on March 31, 2022, which provides certain remedies to the Company, if Biofrontera AG fails to make timely reimbursements, which the Company may implement in its sole discretion, including the ability to charge interest at a rate of 6.0% per annum for each day that any reimbursement is past due and the ability to offset any overdue reimbursement amounts against payments owed to Biofrontera AG by the Company
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1800000	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1800000	usd
CY2023	us-gaap	Debt Instrument Credit Rating DebtInstrumentCreditRating	The IBR for the twelve months ended December 31, 2023 was 9.5%. Given the absence of an outstanding debt agreement for the twelve months ended December 31, 2022, a synthetic credit rating analysis was used in estimating the Company’s IBR. Based on a synthetic credit rating of Ba3 and a term of 3.33 to six years, the IBR was determined to be 6% for lease liabilities at inception and 8.5% for 2022 lease liabilities. No adjustments to the right-of-use asset were required for items such as initial direct costs paid or incentives received.
CY2023	us-gaap	Product Warranty Expense ProductWarrantyExpense	100000	usd
CY2022	us-gaap	Product Warranty Expense ProductWarrantyExpense	100000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Advertising Expense AdvertisingExpense	200000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	100000	usd
CY2023	BFRI	Release Of Contingent Consideration ReleaseOfContingentConsideration	-2500000	usd
CY2023	BFRI	Release Of Startup Cost Financing ReleaseOfStartupCostFinancing	-7300000	usd
CY2023	BFRI	Transfer Of Investment TransferOfInvestment	2415000	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	7385000	usd
CY2023Q4	BFRI	Stock Issued During Period Shares Investment In Equity Securities StockIssuedDuringPeriodSharesInvestmentInEquitySecurities	177465	shares
CY2022Q4	BFRI	Stock Issued During Period Shares Investment In Equity Securities StockIssuedDuringPeriodSharesInvestmentInEquitySecurities	6466946	shares
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	6200000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-3800000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2400000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	100000	usd
CY2023	BFRI	Business Combination Contingent Consideration Arrangements Change In Amount Of Release Of Contingent Consideration Liability BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfReleaseOfContingentConsiderationLiability	-2500000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	100000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-3800000	usd
CY2022Q4	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	2843000	usd
CY2021Q4	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	12854000	usd
CY2023	BFRI	Fair Value Warrant Issuance Of New Derivative Liabilities FairValueWarrantIssuanceOfNewDerivativeLiabilities	6778000	usd
CY2022	BFRI	Fair Value Warrant Issuance Of New Derivative Liabilities FairValueWarrantIssuanceOfNewDerivativeLiabilities	13217000	usd
CY2022	BFRI	Fair Value Warrant Exercise Of Derivative Liabilities FairValueWarrantExerciseOfDerivativeLiabilities	-6840000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6456000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19017000	usd
CY2023	BFRI	Warrant Inducement Expense WarrantInducementExpense	1045000	usd
CY2022	BFRI	Warrant Inducement Expense WarrantInducementExpense	2629000	usd
CY2023Q4	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	4210000	usd
CY2022Q4	BFRI	Fair Value Warrant Liability Purchase Warrant FairValueWarrantLiabilityPurchaseWarrant	2843000	usd
CY2021Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	246000	usd
CY2022	BFRI	Revenue From Contract With Customer Allowances And Reserves Provision Related To Current Period RevenueFromContractWithCustomerAllowancesAndReservesProvisionRelatedToCurrentPeriod	813000	usd
CY2022	BFRI	Revenue From Contract With Customer Allowances And Reserves Credit Payments Made During Period RevenueFromContractWithCustomerAllowancesAndReservesCreditPaymentsMadeDuringPeriod	977000	usd
CY2022Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	82000	usd
CY2022Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	82000	usd
CY2023	BFRI	Revenue From Contract With Customer Allowances And Reserves Provision Related To Current Period RevenueFromContractWithCustomerAllowancesAndReservesProvisionRelatedToCurrentPeriod	507000	usd
CY2023	BFRI	Revenue From Contract With Customer Allowances And Reserves Credit Payments Made During Period RevenueFromContractWithCustomerAllowancesAndReservesCreditPaymentsMadeDuringPeriod	477000	usd
CY2023Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	112000	usd
CY2023Q4	BFRI	Revenue From Contract With Customer Allowances And Reserves RevenueFromContractWithCustomerAllowancesAndReserves	112000	usd
CY2023	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	600000	usd
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-7421000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1747000	usd
CY2023	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	7219000	usd
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-202000	usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-1747000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	200000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	100000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	305000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	439000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	85000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	120000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	286000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	425000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	810000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	691000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	711000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	557000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	507000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	134000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	204000	usd
CY2023Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	15000	usd
CY2023Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2022Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1986000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1568000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2629000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3032000	usd
CY2023Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2022Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	4600000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2185000	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1000000.0	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1343000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17208000	usd
CY2023Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	200000	usd
CY2022Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	200000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1543000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17408000	usd
CY2023Q4	BFRI	Accrued Legal Settlement Expenses Current AccruedLegalSettlementExpensesCurrent	403000	usd
CY2022Q4	BFRI	Accrued Legal Settlement Expenses Current AccruedLegalSettlementExpensesCurrent	6207000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2850000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1064000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1353000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	118000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	40000	usd
CY2023Q4	BFRI	Accrued Product Revenue Allowances And Reserves AccruedProductRevenueAllowancesAndReserves	149000	usd
CY2022Q4	BFRI	Accrued Product Revenue Allowances And Reserves AccruedProductRevenueAllowancesAndReserves	82000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	568000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	332000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4487000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10864000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0521	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0585	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0048	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.3793	pure
CY2023	BFRI	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contingent Consideration EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsideration	-0.0010	pure
CY2022	BFRI	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contingent Consideration EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsideration	1.3362	pure
CY2023	BFRI	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liabilities EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities	0.0327	pure
CY2022	BFRI	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liabilities EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilities	5.7627	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0.0261	pure
CY2023	BFRI	Effective Income Tax Rate Reconciliation Trueups EffectiveIncomeTaxRateReconciliationTrueups	-0.0008	pure
CY2022	BFRI	Effective Income Tax Rate Reconciliation Trueups EffectiveIncomeTaxRateReconciliationTrueups	-0.0742	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0004	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3161	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-6.8554	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0014	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0585	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36964000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30450000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	8000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4270000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4824000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	96000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	129000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	123000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	393000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	890000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	711000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	449000	usd
CY2023Q4	BFRI	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	391000	usd
CY2022Q4	BFRI	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	361000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	40000	usd
CY2023Q4	BFRI	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	422000	usd
CY2022Q4	BFRI	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	369000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	43000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	-469000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	42527000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	36163000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42527000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36163000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6400000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	148600000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	111500000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	139000000.0	usd
CY2023Q4	BFRI	Legal Settlements Receivable Percentage LegalSettlementsReceivablePercentage	0.50	pure
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	219477	shares
CY2021Q4	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	99.69
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	463686	shares
CY2022	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceIssued	35.77
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	221307	shares
CY2022	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceExercised	20.92
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	461856	shares
CY2022Q4	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	52.29
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	2862500	shares
CY2023	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePriceIssued	2.24
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3324356	shares
CY2023Q4	BFRI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	2.46
CY2023Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-20 reverse stock split
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	214286	shares
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4600000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	BFRI	Share Exercise Price ShareExercisePrice	5.00
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	6.40
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	29.28
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	30737	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	95.40
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y11M8D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1691000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	64572	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	48.20
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	8358	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	76.11
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	86951	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	62.16
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M7D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	49730	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.35
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	37195	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	52.55
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	99486	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	39.36
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M14D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	27815	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	67.54
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y1M20D
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	900000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2023	us-gaap	Interest Expense InterestExpense	220000	usd
CY2022	us-gaap	Interest Expense InterestExpense	12000	usd
CY2023	BFRI	Interest Expenses Related Party InterestExpensesRelatedParty	22000	usd
CY2023	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	358000	usd
CY2022	BFRI	Contract Asset Interest Expense ContractAssetInterestExpense	358000	usd
CY2022	us-gaap	Interest Income Operating InterestIncomeOperating	165000	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	132000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	10000	usd
CY2023	BFRI	Interest Expense Net InterestExpenseNet	468000	usd
CY2022	BFRI	Interest Expense Net InterestExpenseNet	195000	usd
CY2023	BFRI	Gainloss On Termination Of Operating Leases GainlossOnTerminationOfOperatingLeases	134000	usd
CY2022	BFRI	Gainloss On Termination Of Operating Leases GainlossOnTerminationOfOperatingLeases	93000	usd
CY2023	BFRI	Foreign Currency Transactions ForeignCurrencyTransactions	-114000	usd
CY2022	BFRI	Foreign Currency Transactions ForeignCurrencyTransactions	-28000	usd
CY2023	BFRI	Bank Service Charges BankServiceCharges	-92000	usd
CY2022	BFRI	Bank Service Charges BankServiceCharges	-8000	usd
CY2023	BFRI	Other Nonoperating Income Net OtherNonoperatingIncomeNet	-3000	usd
CY2022	BFRI	Other Nonoperating Income Net OtherNonoperatingIncomeNet	-24000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-75000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	752000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	733000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20131000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-640000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1546297	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1546297	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1056988	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1056988	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.02
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-13.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2393795000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	584165000	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2393795000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	584165000	shares
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	option to extend the term of the lease for one five (5) year period
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	560000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	653000	usd
CY2023	BFRI	Interest On Lease Liabilities InterestOnLeaseLiabilities	84000	usd
CY2022	BFRI	Interest On Lease Liabilities InterestOnLeaseLiabilities	99000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	644000	usd
CY2023Q4	us-gaap	Subsequent Event Description SubsequentEventDescription	we received a letter (the “Notice”) from the Listing Qualifications Staff of Nasdaq notifying us that, because our stockholders’ equity as reported in our Quarterly Report on Form 10-Q for the period ended September 30, 2023 was $1,038,000, we are no longer in compliance with the continued listing requirement under Nasdaq Listing Rule 5550(b)(1), which requires that a listed company’s stockholders’ equity be at least $2,500,000. Additionally, as of the date of the Notice, the Company did not meet either of the alternative requirements of maintaining a market value of listed securities of $35 million or achieving a net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years. As a result, as of the date of this Form 10-K, we do not satisfy Nasdaq Marketplace Rule 5550(b)
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	781000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	800000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	234000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y2M19D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M14D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0776	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0631	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	779000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	587000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	238000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	31000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1635000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	140000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1495000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	691000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	804000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1495000	usd
CY2021Q4	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	22500000	usd
CY2023	BFRI	Percentage Of Common Stock Outstanding PercentageOfCommonStockOutstanding	0.20	pure
CY2023	us-gaap	Description Of Nature And Effect Of Significant Changes During Period Affecting Comparability DescriptionOfNatureAndEffectOfSignificantChangesDuringPeriodAffectingComparability	The Company matches 50% of employee contributions up to a maximum of 6% of employees’ salary.
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd

Files In Submission

Name	View Source	Status
0001493152-24-010133-index-headers.html	Edgar Link	pending
0001493152-24-010133-index.html	Edgar Link	pending
0001493152-24-010133.txt	Edgar Link	pending
0001493152-24-010133-xbrl.zip	Edgar Link	pending
bfri-20231231.xsd	Edgar Link	pending
ex10-34.htm	Edgar Link	pending
ex10-35.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
ex97.htm	Edgar Link	pending
ex97_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
bfri-20231231_def.xml	Edgar Link	unprocessable
bfri-20231231_lab.xml	Edgar Link	unprocessable
bfri-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bfri-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BFRI
Biofrontera Inc Stock $bfri

2024 Q1 Form 10-K Financial Statement

#000149315224010133 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFRI Biofrontera Inc Stock $bfri

2024 Q1 Form 10-K Financial Statement

#000149315224010133 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BFRI
Biofrontera Inc Stock $bfri